Meeting
2013 ASCO Annual Meeting
A survey of thousands of tumor exomes and transcriptomes to expand clinical opportunities for crizotinib.
Authors
Emma Bowden
Compendia Bioscience, Ann Arbor, MI
Emma Bowden , Sean Eddy , Paul Williams , Nikolay Khazanov , Armand Bankhead III, Dinesh Cyanam , Peter Wyngaard , Dan Rhodes
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Tumor Biology
Track
Tumor Biology
Sub Track
Genomic and Epigenomic Biomarkers
Citation
J Clin Oncol 31, 2013 (suppl; abstr 11017)
DOI
10.1200/jco.2013.31.15_suppl.11017
Abstract #
11017
Poster Bd #
6
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
An amplicon-based liquid biopsy for detecting ALK and ROS1 fusions and resistance mutations in advanced non-small cell lung cancer (NSCLC) patients.
First Author: Laura Mezquita
Poster
2022 ASCO Annual Meeting
Phase 3 trial of lorlatinib in treatment-naive patients (Pts) with ALK-positive advanced non–small cell lung cancer (NSCLC): Comprehensive plasma and tumor genomic analyses.
First Author: Alessandra Bearz
Poster
2020 ASCO Virtual Scientific Program
Longitudinal monitoring by next generation sequencing of plasma cell-free DNA in ALK-rearranged non-small cell lung cancer (NSCLC) patients treated with ALK tyrosine kinase inhibitors.
First Author: Minsuk Kwon
Poster
2020 ASCO Virtual Scientific Program
Correlation of baseline molecular and clinical variables with ALK inhibitor efficacy in ALTA-1L.
First Author: D. Ross Camidge